Company News: Curetis Announces Preliminary, Unaudited 2019 Condensed Combined Key Financials and Provides Business Update
— Revenue increases by 64% to EUR 2.3 million, up from 1.4 million in 2018
— More than tripled total contract order volume received year-over-year to about EUR 3.4 million 2019
— Curetis N.V. shareholders to vote on March 10, 2020 on planned business combination with OpGen, Inc.
Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced preliminary. unaudited condensed combined key financials for the fiscal year 2019 and provided a business update for 2020 year-to-date.